Alembic Pharmaceuticals Limited
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Alembic Pharmaceuticals Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 19% to $62,286,300,000. The net income raised on $6,158,200,000 and profit margin reached 10%. Total operating expenses were $15,869,700,000.

Profit Margin

Alembic Pharmaceuticals Limited (NSE:APLLTD.NS): Profit margin
2011 11.98B 853.87M 7.12%
2012 14.66B 1.30B 8.87%
2015 20.09B 2.82B 14.08%
2016 30.54B 7.19B 23.55%
2018 30.35B 4.12B 13.6%
2019 38.06B 5.84B 15.35%
2021 52.76B 11.46B 21.73%
2022 52.31B 5.20B 9.96%
2024 62.28B 6.15B 9.89%

APLLTD.NS Income Statement (2011 – 2023)

2023 2021 2020 2018 2017 2015 2014 2012 2011
Revenue
Revenue
62.28B52.31B52.76B38.06B30.35B30.54B20.09B14.66B11.98B
Cost of revenue
39.59B17.23B15.21B11.93B10.62B8.42B7.58B7.07B6.52B
Gross profit
22.68B35.08B37.54B26.13B19.72B22.12B12.51B7.58B5.46B
Operating exp.
Research and development
4.38B505.9M253.8M302.7M368.6M3.07B1.21B585.82M471.31M
Selling and marketing
9.96B8.90B6.96B5.90B3.80B2.73B2.44B1.08B1.13B
Total operating expenses
15.86B29.16B24.58B18.55B14.63B12.76B8.98B5.65B4.15B
Operating income
5.75B5.87B12.96B7.41B5.09B9.35B3.53B1.93B1.30B
Other income (expenses), net
560.2M379.3M-9.63B-12.8M314.1M-900K58.86M-323.30M238.88M
Income before tax
6.31B6.20B13.68B7.49B5.41B9.35B3.59B1.60B1.06B
Income tax expense
160M1.04B2.53B1.56B1.20B2.16B763.49M308.49M214.55M
Net income
6.15B5.20B11.46B5.84B4.12B7.19B2.82B1.30B853.87M
Earnings per share
Basic EPS
31.3326.559.183121.8938.1915.016.94.53
Diluted EPS
31.3326.559.183121.8938.1915.016.94.53
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source